Literature DB >> 12649092

Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences.

Gunilla Nordin Fredrikson1, Ingrid Söderberg, Marie Lindholm, Paul Dimayuga, Kuang-Yuh Chyu, Prediman K Shah, Jan Nilsson.   

Abstract

OBJECTIVE: LDL oxidation is believed to play an important role in the development of atherosclerosis, and oxidized LDL particles have been shown to become targets for the immune system. Immunization of animals with oxidized LDL results in reduction of atherosclerosis, suggesting an atheroprotective effect of this immune response. METHODS AND
RESULTS: Using a polypeptide library covering the complete sequence of apoB-100, a large number of native and malondialdehyde-modified peptide sequences in apoB-100 that are recognized by antibodies in human plasma were identified. We report here that immunization with apoB-100 peptide sequences, against which high levels of IgG and IgM antibodies are present in healthy human controls, reduce atherosclerosis in apoE-null mice by about 60%. Immunizations with these peptides were also found to increase the collagen content of subvalvular lesions.
CONCLUSIONS: These studies have identified peptide sequences in apoB-100 that induce immune responses, which inhibits atherosclerosis. This suggests a way of developing an immunization therapy for coronary heart disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12649092     DOI: 10.1161/01.ATV.0000067937.93716.DB

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  69 in total

Review 1.  Advances in understanding mechanisms and therapeutic targets to treat comorbid depression and cardiovascular disease.

Authors:  Brittany S Pope; Susan K Wood
Journal:  Neurosci Biobehav Rev       Date:  2020-06-26       Impact factor: 8.989

Review 2.  How Oxidized Low-Density Lipoprotein Activates Inflammatory Responses.

Authors:  Jillian P Rhoads; Amy S Major
Journal:  Crit Rev Immunol       Date:  2018       Impact factor: 2.214

Review 3.  Immunomodulation of vascular diseases: atherosclerosis and autoimmunity.

Authors:  G-P Shi
Journal:  Eur J Vasc Endovasc Surg       Date:  2010-02-25       Impact factor: 7.069

Review 4.  Advances in immune-modulating therapies to treat atherosclerotic cardiovascular diseases.

Authors:  Kuang-Yuh Chyu; Prediman K Shah
Journal:  Ther Adv Vaccines       Date:  2014-03

Review 5.  B cells and atherosclerosis.

Authors:  Prasad Srikakulapu; Coleen A McNamara
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-03-17       Impact factor: 4.733

Review 6.  Vaccine against arteriosclerosis: an update.

Authors:  Kuang-Yuh Chyu; Paul C Dimayuga; Prediman K Shah
Journal:  Ther Adv Vaccines       Date:  2017-02-01

Review 7.  Vaccination against atherosclerosis.

Authors:  Kouji Kobiyama; Ryosuke Saigusa; Klaus Ley
Journal:  Curr Opin Immunol       Date:  2019-03-29       Impact factor: 7.486

Review 8.  Regulatory T cells in atherosclerosis: critical immune regulatory function and therapeutic potential.

Authors:  Charlotte Spitz; Holger Winkels; Christina Bürger; Christian Weber; Esther Lutgens; Göran K Hansson; Norbert Gerdes
Journal:  Cell Mol Life Sci       Date:  2015-10-30       Impact factor: 9.261

9.  Surface engineered polymersomes for enhanced modulation of dendritic cells during cardiovascular immunotherapy.

Authors:  Sijia Yi; Xiaohan Zhang; Hussain Sangji; Yugang Liu; Sean D Allen; Baixue Xiao; Sharan Bobbala; Cameron L Braverman; Lei Cai; Peter I Hecker; Mathew DeBerge; Edward B Thorp; Ryan E Temel; Samuel I Stupp; Evan A Scott
Journal:  Adv Funct Mater       Date:  2019-08-12       Impact factor: 18.808

10.  Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E.

Authors:  Kathrin S Michelsen; Michelle H Wong; Prediman K Shah; Wenxuan Zhang; Juliana Yano; Terence M Doherty; Shizuo Akira; Tripathi B Rajavashisth; Moshe Arditi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.